Indian startup Bugworks Research secures $18M to advance work in AMR
Indian startup Bugworks Research, with operations in US and Australia, has announced the financing of $18M Series B1. This round will support the clinical development of BWC0977, a novel broad spectrum anti-bacterial agent available in both IV and oral forms, and the pre-clinical development of its best-in-class Adenosine immuno-oncology asset.
Bugworks will continue to invest in its proprietary drug discovery platforms GYROX (for AMR) and DARE (for IO), and identify new drugs for serious, underserved indications.
Bugworks’ lead Antibacterial asset BWC0977 continues to be supported by CARB-X, the global non-profit partnership dedicated to accelerating antibacterial research to tackle the global threat of drug-resistant bacteria.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.